Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
$0.00
$0.00
$0.00
N/A1.98N/AN/A
Affymax Inc. stock logo
AFFY
Affymax
$0.00
$0.00
$0.00
$0.00
N/A7.341,891 shs200 shs
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
$0.00
$0.00
$0.00
$0.00
N/A1.8210 shs553 shs
Poxel France stock logo
PXXLF
Poxel France
$0.25
$0.25
$0.25
$0.25
N/A-0.4N/AN/A
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
0.00%0.00%0.00%0.00%0.00%
Affymax Inc. stock logo
AFFY
Affymax
0.00%0.00%+700.00%0.00%+14.29%
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Poxel France stock logo
PXXLF
Poxel France
0.00%0.00%0.00%0.00%-64.29%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
N/AN/AN/AN/AN/AN/AN/AN/A
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/AN/AN/AN/AN/AN/A
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Poxel France stock logo
PXXLF
Poxel France
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
0.00
N/AN/AN/A
Affymax Inc. stock logo
AFFY
Affymax
0.00
N/AN/AN/A
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
0.00
N/AN/AN/A
Poxel France stock logo
PXXLF
Poxel France
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
N/AN/AN/AN/AN/AN/A
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/AN/AN/AN/A
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/AN/AN/AN/A
Poxel France stock logo
PXXLF
Poxel France
$710KN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Affymax Inc. stock logo
AFFY
Affymax
N/AN/A0.00N/AN/AN/AN/AN/A
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/A
Poxel France stock logo
PXXLF
Poxel France
-$33.08MN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
N/AN/AN/AN/AN/A
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/AN/AN/A
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/AN/AN/A
Poxel France stock logo
PXXLF
Poxel France
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
N/A
Affymax Inc. stock logo
AFFY
Affymax
N/A
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/A
Poxel France stock logo
PXXLF
Poxel France
N/A

Insider Ownership

CompanyInsider Ownership
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
17.40%
Affymax Inc. stock logo
AFFY
Affymax
1.55%
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
2.08%
Poxel France stock logo
PXXLF
Poxel France
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
6N/AN/ANot Optionable
Affymax Inc. stock logo
AFFY
Affymax
4N/AN/ANot Optionable
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
20N/AN/ANot Optionable
Poxel France stock logo
PXXLF
Poxel France
15N/AN/ANot Optionable

Recent News About These Companies

Poxel : va présenter des données sur l'Imeglimine
Google Pixel 10: Ultimate Preview Guide

Media Sentiment Over Time

Alliqua BioMedical stock logo

Alliqua BioMedical OTCMKTS:ADYX

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

Affymax stock logo

Affymax OTCMKTS:AFFY

$0.0008 0.00 (0.00%)
As of 07/9/2025 01:30 PM Eastern

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

Anthera Pharmaceuticals stock logo

Anthera Pharmaceuticals OTCMKTS:ANTH

$0.0001 0.00 (0.00%)
As of 07/9/2025 09:30 AM Eastern

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

Poxel France stock logo

Poxel France OTCMKTS:PXXLF

$0.25 0.00 (0.00%)
As of 07/8/2025

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.